Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 11.00 GBp
Change Today 0.00 / 0.00%
Volume 386.3K
As of 11:35 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

oxford pharmascience group p (OXP) Snapshot

Open
11.00 GBp
Previous Close
11.00 GBp
Day High
11.00 GBp
Day Low
11.00 GBp
52 Week High
04/15/15 - 11.50 GBp
52 Week Low
12/10/14 - 3.23 GBp
Market Cap
110.6M
Average Volume 10 Days
2.2M
EPS TTM
-0.0028 GBp
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXFORD PHARMASCIENCE GROUP P (OXP)

Related News

No related news articles were found.

oxford pharmascience group p (OXP) Related Businessweek News

No Related Businessweek News Found

oxford pharmascience group p (OXP) Details

Oxford Pharmascience Group Plc, a specialty pharmaceutical company, re-develops medicines using proprietary technology platforms in the United Kingdom, Brazil, the Middle East, the Far East, and internationally. The company’s product pipeline includes programs in non-steroidal anti-inflammatory drugs comprising Ibuprofen, Naproxen, Diclofenac, and Aspirin, as well as statins, such as Atorvastatin for pain relief and cardiovascular disease indications. It also provides calcium/vitamin D chews that taste better and dissolve faster. The company was formerly known as Oxford Nutrascience Group Plc and changed its name to Oxford Pharmascience Group Plc in May 2011. Oxford Pharmascience Group Plc was founded in 2008 and is based in London, the United Kingdom.

Founded in 2008

oxford pharmascience group p (OXP) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: 150.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 8.0K GBP
Compensation as of Fiscal Year 2013.

oxford pharmascience group p (OXP) Key Developments

Oxford Pharmascience Announces Pilot Comparative Pharmacokinetics Study of OXPzero™ Naproxen

Oxford Pharmascience announced that the pilot comparative pharmacokinetics study of OXPzero™ Naproxen, which commenced on 5 March, has been successful and the headline data from the trial demonstrates bioequivalence of OXP005 to Naprosyn® (generic naproxen). OXPzero™ Naproxen aims to deliver 250mg of reduced gastric irritation naproxen via the Company's patent protected OXPzero™ technology in an immediate release oral formulation in order to provide a significantly reduced gastrointestinal (GI) side effect profile compared to standard naproxen tablets. The headline PK data showed results which demonstrate bioequivalence and that the OXPzero™technology has been successfully optimised to enable immediate and complete drug release. Full results of the study will be published in the following weeks. Based on this data, the company will now progress to a proof of concept endoscopy study to demonstrate the reduced GI irritation benefit of OXPzero™ Naproxen, as was previously demonstrated for OXPzero™ Ibuprofen in an earlier formulation. Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used classes of drugs, with combined annual sales in excess of $12 billion and more than 30 million users worldwide consuming NSAIDs each day (source: Evaluate Pharma). Chronic use of NSAIDs causes well-documented GI side effects, including ulcers and bleeding, and leads to significant morbidity and mortality in a substantial number of patients, with significant associated healthcare costs. The OXPzero™ platform technology reduces these risks and is being selectively applied to the most commonly used NSAID molecules, namely ibuprofen, naproxen, diclofenac and aspirin.

Oxford Pharmascience Group plc Announces Consolidated Earnings Results for the Year Ended Dec. 31, 2014

Oxford Pharmascience Group Plc announced consolidated earnings results for the year ended Dec. 31, 2014. For the year, the company reported revenues of £705,000, operating loss of £3,496,000, loss before income tax of £3,604,000, loss after tax attributable to equity holders of the partner of £2,864,000 or £0.29 per basic and diluted share net cash outflow from operating activities of £3,422,000, purchases of property, plant and equipment of £2,000 compared to the revenues of £1,029,000, operating loss of £1,558,000, loss before income tax £1,536,000, loss after tax attributable to equity holders of the partner of £1,487,000 or £0.17 per basic and diluted share net cash outflow from operating activities of £1,227000, purchases of property, plant and equipment of £2,000 for the previous year.

Oxford Pharmascience Group plc Provides Earnings Guidance for the Year Ended December 31, 2014

Oxford Pharmascience Group Plc provided earnings guidance for the year ended December 31, 2014. The company now expects revenue for the year to 31 December 2014 to be around £0.7 million. The Loss Before Tax for the year ended 31 December 2014 is expected to be in the region of £3.5 million, which reflects the acceleration in 2014 of R&D investment in the NSAIDs programme.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXP:LN 11.00 GBp 0.00

OXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXP.
View Industry Companies
 

Industry Analysis

OXP

Industry Average

Valuation OXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 151.0x
Price/Book 14.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 150.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD PHARMASCIENCE GROUP P, please visit www.oxfordpharmascience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.